Iomab-B

Candidate & Indication Development Stage
R & D Preclinical Phase 1 Phase 2 Phase 3
Iomab-B CD451 BMT (Bone Marrow Transplant)
Patients over age 55 with relapsed or refractory AML
Induction and conditioning agent prior to a BMT
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
  1. BMT or HSCT (Hematopoietic Stem Cell Transplantation) is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.

Iomab-B (BC8-I-131 construct), via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells. Once attached to its target cells, the radioisotope, I-131, emits energy that travels a relatively long distance, destroying a patient's cancer cells and bone marrow. Iomab-B is currently in a pivotal Phase 3 trial and it is intended, upon approval, to be an induction and conditioning agent prior to a bone marrow transplant for relapsed and refractory Acute Myeloid Leukemia (AML) patients over the age of 55.

Iomab-B has already been used as a myeloconditioning/myeloablative agent in almost 300 patients with hematologic malignancies. In both Phase 1 and Phase 2 clinical trials Iomab-B has generated promising results and continues to be studied at the Fred Hutchinson Cancer Research Center in several ongoing physician sponsored clinical trials beyond AML including Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Hodgkin's Disease and Non-Hodgkin Lymphoma.